What first‑line mood stabilizer and dosing schedule should be used for an older adult with dementia who has agitation, aggression, or mood lability?

First-Line Mood Stabilizer for Agitation, Aggression, and Mood Lability in Dementia

Divalproex sodium (Depakote) is the preferred first-line mood stabilizer for older adults with dementia experiencing agitation, aggression, or mood lability, starting at 125 mg twice daily and titrating to therapeutic blood levels of 40-90 mcg/mL, though it should only be used after exhausting non-pharmacological interventions and when symptoms are severe, dangerous, or cause significant distress. 1

Critical Context: When to Consider Mood Stabilizers

Before initiating any mood stabilizer, you must:

• Exhaust non-pharmacological interventions first - these are the true first-line treatments for behavioral and psychological symptoms of dementia (BPSD) 2
• Reserve pharmacological treatment only for severe, dangerous symptoms or those causing significant patient distress 2
• Assess for and treat reversible causes including pain, urinary retention, constipation, hypoxia, and medication side effects 1, 2

Specific Mood Stabilizer Recommendations

Divalproex Sodium (First Choice)

Dosing schedule:

• Initial: 125 mg twice daily 1
• Titrate to therapeutic blood level: 40-90 mcg/mL 1
• Monitor liver enzymes regularly 1
• Monitor platelets, PT, and PTT as indicated 1

Rationale: Divalproex is "generally better tolerated than other mood stabilizers" in elderly patients with dementia 1. While controlled studies have not definitively proven efficacy 3, it demonstrates fewer adverse effects and drug-drug interactions compared to alternatives like carbamazepine 4. Open studies show 80% of patients achieved ≥50% reduction in behavioral agitation episodes 5.

Carbamazepine (Alternative Option)

Dosing schedule:

• Initial: 100 mg twice daily 1
• Titrate to therapeutic blood level: 4-8 mcg/mL 1
• Monitor CBC and liver enzymes regularly 1

Rationale: Carbamazepine is the only anticonvulsant mood stabilizer with proven efficacy in controlled studies for BPSD 6, 3. However, it has "problematic side effects" including sedation, hyponatremia, cardiac toxicity, and significant drug-drug interactions due to enzyme induction 1, 3. Use only when divalproex is contraindicated or not tolerated.

Trazodone (For Agitation with Sleep Disturbance)

Dosing schedule:

• Initial: 25 mg per day 1
• Maximum: 200-400 mg per day in divided doses 1
• Use with caution in patients with premature ventricular contractions 1

Rationale: Listed as a mood-stabilizing/antiagitation drug, particularly useful for severe agitated, repetitive, and combative behaviors 1.

Medications to Avoid

Do NOT use:

• Valproate preparations - consistent evidence shows they should not be used for agitation and aggression in dementia 6
• Topiramate - deleterious effects on cognitive function 3
• Benzodiazepines as first-line - risk of tolerance, addiction, depression, cognitive impairment, and paradoxical agitation in ~10% of patients 1

Monitoring and Discontinuation

Reassess treatment at 4 weeks:

• If no clinically significant response after 4 weeks at adequate dose, taper and withdraw the medication 2
• Monitor for side effects continuously; if significant side effects occur, review risk/benefit and consider discontinuation 2

For positive responders:

• Continue monitoring with quantitative measures 2
• Discuss ongoing treatment with patient (if feasible) and surrogate decision makers 2
• Consider gradual dose reduction after 9 months to reassess need 1

Adjunctive Considerations

If mood stabilizers are insufficient:

• Consider adding cholinesterase inhibitors, which may improve behavioral symptoms 7, 8
• For depression specifically, SSRIs (citalopram, sertraline) are first-line antidepressants with minimal anticholinergic effects 1, 7, 8
• Antipsychotics should be reserved as carefully monitored, short-term, last resort only for clear and imminent risk of harm 9, 2

Common Pitfalls to Avoid

• Starting without adequate non-pharmacological trial - this violates evidence-based guidelines 2
• Using antipsychotics before mood stabilizers - antipsychotics carry increased mortality risk and should be last resort 9, 2
• Failing to monitor therapeutic drug levels - both divalproex and carbamazepine require blood level monitoring for efficacy and safety 1
• Continuing treatment indefinitely without reassessment - regular evaluation for continued need is essential 1, 2